Thromboxane A2 receptor: Biology and function of a peculiar receptor that remains resistant for therapeutic targeting

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 17, Issue 3, 2012, Pages 248-259

  Ting, Harold J ^a   Murad, John P ^a   Espinosa, Enma V P ^a   Khasawneh, Fadi T ^a  

^a WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

Author keywords

antiplatelet therapy; drug rediscovery; platelets; thrombosis; thromboxane A2 receptor

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 3 [(4 TERT BUTYL 2 THIAZOLYL)METHOXY] 5' [3 (4 CHLOROBENZENESULFONYL)PROPYL] 2' (1H TETRAZOL 5 YLMETHOXY)BENZANILIDE; 7 [3 [(4 PHENYLSEMICARBAZIDO)METHYL] 7 OXABICYCLO[2.2.1]HEPT 2 YL] 5 HEPTENOIC ACID; ACETYLSALICYLIC ACID; BM 520; BM 531; BM 567; DALTROBAN; DAZMEGREL; DAZOXIBEN; DICLOFENAC; DOMITROBAN; FUREGRELATE; GLIBENCLAMIDE; IFETROBAN; IMITRODAST; IRBESARTAN; ISBOGREL; LOSARTAN; LUMIRACOXIB; MITOGEN ACTIVATED PROTEIN KINASE 3; NONSTEROID ANTIINFLAMMATORY AGENT; OZAGREL; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE; PICOTAMIDE; PIRMAGREL; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; RIDOGREL; SERATRODAST; SULOTROBAN; TERBOGREL; TERUTROBAN; THROMBOXANE A2 RECEPTOR; TORASEMIDE; UNCLASSIFIED DRUG; VAPIPROST;

ACUTE HEART INFARCTION; ANTIINFLAMMATORY ACTIVITY; ARTERY THROMBOSIS; ASTHMA; BINDING AFFINITY; BINDING KINETICS; BIOTRANSFORMATION; CARBOXY TERMINAL SEQUENCE; COMPETITIVE INHIBITION; CYTOKINESIS; DOSE RESPONSE; DOWN REGULATION; DRUG BIOAVAILABILITY; DRUG INDICATION; DRUG RESEARCH; DRUG TARGETING; EXON; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPERTENSION; LIGAND BINDING; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MODIFICATION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOGENESIS; VASCULAR SMOOTH MUSCLE;

ANTICOAGULANTS; BLOOD PLATELETS; DRUG DESIGN; GENE EXPRESSION REGULATION; HUMANS; RECEPTORS, THROMBOXANE A2, PROSTAGLANDIN H2; THROMBOSIS;

EID: 84865107306     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/1074248411424145     Document Type: Review

References (130)

1. Du X. Signaling and regulation of the platelet glycoprotein ib-ix-v complex. Curr Opin Hematol. 2007 ; 14 (3). 262-269 (Pubitemid 46597613)
2. Baglia FA, Shrimpton CN, Emsley J, Kitagawa K, Ruggeri ZM, Lopez JA, et al. Factor xi interacts with the leucine-rich repeats of glycoprotein ibalpha on the activated platelet. J Biol Chem. 2004 ; 279 (47). 49323-49329 (Pubitemid 39625819)
3. Landis RC.. Protease activated receptors: clinical relevance to hemostasis and inflammation. Hematol Oncol Clin North Am. 2007 ; 21 (1). 103-113 (Pubitemid 46164771)
4. Reilly M, Fitzgerald GA. Cellular activation by thromboxane a2 and other eicosanoids. Eur Heart J. 1993 ; 14 (suppl K). 88-93 (Pubitemid 24038961)
5. Brisson C, Azorsa DO, Jennings LK, Moog S, Cazenave JP, Lanza F. Co-localization of cd9 and gpiib-iiia (alpha iib beta 3 integrin) on activated platelet pseudopods and alpha-granule membranes. Histochem J. 1997 ; 29 (2). 153-165 (Pubitemid 27192190)
6. Born GV. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature. 1962 ; 194: 927-929
7. Halushka PV, Mais DE, Mayeux PR, Morinelli TA. Thromboxane, prostaglandin and leukotriene receptors. Annu Rev Pharmacol Toxicol. 1989 ; 29: 213-239 (Pubitemid 19107353)
8. Hirata M, Hayashi Y, Ushikubi F, Yokota Y, Kageyama R, Nakanishi S, et al. Cloning and expression of cdna for a human thromboxane a2 receptor. Nature. 1991 ; 349 (6310). 617-620 (Pubitemid 21912117)
9. Kim SO, Lim CT, Lam SC, Hall SE, Komiotis D, Venton DL, et al. Purification of the human blood platelet thromboxane a2/prostaglandin h2 receptor protein. Biochem Pharmacol. 1992 ; 43 (2). 313-322
10. Giannarelli C, Zafar MU, Badimon JJ. Prostanoid and tp-receptors in atherothrombosis: is there a role for their antagonism?. Thromb Haemost. 2010 ; 104 (5). 949-954
11. Parise LV, Venton DL, Le Breton GC. Arachidonic acid-induced platelet aggregation is mediated by a thromboxane a2/prostaglandin h2 receptor interaction. J Pharmacol Exp Ther. 1984 ; 228 (1). 240-244 (Pubitemid 14223408)
12. Khasawneh FT, Huang JS, Mir F, Srinivasan S, Tiruppathi C, Le Breton GC. Characterization of isoprostane signaling: evidence for a unique coordination profile of 8-iso-pgf(2alpha) with the thromboxane a(2) receptor, and activation of a separate camp-dependent inhibitory pathway in human platelets. Biochem Pharmacol. 2008 ; 75 (12). 2301-2315
13. Brass LF, Manning DR, Cichowski K, Abrams CS. Signaling through g proteins in platelets: To the integrins and beyond. Thromb Haemost. 1997 ; 78 (1). 581-589 (Pubitemid 27289308)
14. Patrono C, Ciabattoni G, Davi G. Thromboxane biosynthesis in cardiovascular diseases. Stroke. 1990 ; 21 (IV). 130-133
15. Oates JA, FitzGerald GA, Branch RA, Jackson EK, Knapp HR, Roberts LJ. Clinical implications of prostaglandin and thromboxane a2 formation (2). N Engl J Med. 1988 ; 319 (12). 761-767
16. Ogletree ML. Overview of physiological and pathophysiological effects of thromboxane a2. Fed Proc. 1987 ; 46 (1). 133-138 (Pubitemid 17056331)
17. Patrono C. Aspirin as an antiplatelet drug. N Engl J Med. 1994 ; 330: 1287-1294 (Pubitemid 24129964)
18. Clarke RJ, Mayo G, Price P, FitzGerald GA. Suppression of thromboxane a2 but not of systemic prostacyclin by controlled-release aspirin. N Engl J Med. 1991 ; 325 (16). 1137-1141
19. Schlansky B, Hwang JH. Prevention of nonsteroidal anti-inflammatory drug-induced gastropathy. J Gastroenterol. 2009 ; 44 (suppl 19). 44-52
20. Meijer K, Schulman S. Determinants of bleeding risk in patients on antithrombotic and antifibrinolytic drugs. Semin Thromb Hemost. 2008 ; 34 (8). 762-771
21. Pusch G, Feher G, Kotai K, Tibold A, Gasztonyi B, Feher A, et al. Aspirin resistance: focus on clinical endpoints. J Cardiovasc Pharmacol. 2008 ; 52 (6). 475-484
22. Le Breton GC, Venton DL, Enke SE, Halushka PV. 13-azaprostanoic acid: A specific antagonist of the human blood platelet thromboxane/endoperoxide receptor. Proc Natl Acad Sci U S A. 1979 ; 76 (8). 4097-4101 (Pubitemid 9249031)
23. Nicolaou KC, Magolda RL, Smith JB, Aharony D, Smith EF, Lefer AM. Synthesis and biological properties of pinane-thromboxane a2, a selective inhibitor of coronary artery constriction, platelet aggregation, and thromboxane formation. Proc Natl Acad Sci U S A. 1979 ; 76 (6). 2566-2570 (Pubitemid 9213908)
24. Ogletree ML, Harris DN, Greenberg R, Haslanger MF, Nakane M. Pharmacological actions of sq 29,548, a novel selective thromboxane antagonist. J Pharmacol Exp Ther. 1985 ; 234 (2). 435-441 (Pubitemid 15241865)
25. Patscheke H, Stegmeier K, Muller-Beckmann B, Sponer G, Staiger C, Neugebauer G. Inhibitory effects of the selective thromboxane receptor antagonist bm 13.177 on platelet aggregation, vasoconstriction and sudden death. Biomed Biochim Acta. 1984 ; 43 (8-9). S312 - S318
26. Raychowdhury MK, Yukawa M, Collins LJ, McGrail SH, Kent KC, Ware JA. Alternative splicing produces a divergent cytoplasmic tail in the human endothelial thromboxane a2 receptor. J Biol Chem. 1994 ; 269 (30). 19256-19261 (Pubitemid 24233442)
27. Hirata T, Ushikubi F, Kakizuka A, Okuma M, Narumiya S.. Two thromboxane a2 receptor isoforms in human platelets. Opposite coupling to adenylyl cyclase with different sensitivity to arg60 to leu mutation. J Clin Invest. 1996 ; 97 (4). 949-956
28. Habib A, FitzGerald GA, Maclouf J. Phosphorylation of the thromboxane receptor alpha, the predominant isoform expressed in human platelets. J Biol Chem. 1999 ; 274 (5). 2645-2651 (Pubitemid 29075342)
29. Miggin SM, Kinsella BT. Expression and tissue distribution of the mrnas encoding the human thromboxane a2 receptor (tp) alpha and beta isoforms. Biochim Biophys Acta. 1998 ; 1425 (3). 543-559 (Pubitemid 28546689)
30. Geng L, Wu J, So SP, Huang G, Ruan KH. Structural and functional characterization of the first intracellular loop of human thromboxane a2 receptor. Arch Biochem Biophys. 2004 ; 423 (2). 253-265 (Pubitemid 38328435)
31. So SP, Wu J, Huang G, Huang A, Li D, Ruan KH. Identification of residues important for ligand binding of thromboxane a2 receptor in the second extracellular loop using the nmr experiment-guided mutagenesis approach. J Biol Chem. 2003 ; 278 (13). 10922-10927 (Pubitemid 36792638)
32. Findlay JB, Pappin DJ. The opsin family of proteins. Biochem J. 1986 ; 238 (3). 625-642
33. Narumiya S, Hirata N, Namba T, Hayashi Y, Ushikubi F, Sugimoto Y, Negishi M, Ichikawa A. Structure and function of prostanoid receptors. J Lipid Mediat. 1993 ; 6 (1-3). 155-161 (Pubitemid 23152445)
34. Funk CD, Furci L, Moran N, Fitzgerald GA. Point mutation in the seventh hydrophobic domain of the human thromboxane a2 receptor allows discrimination between agonist and antagonist binding sites. Mol Pharmacol. 1993 ; 44 (5). 934-939 (Pubitemid 23344958)
35. Dorn GW, Davis MG, D'Angelo DD. Structural determinants for agonist binding affinity to thromboxane/prostaglandin endoperoxide (tp) receptors. Analysis of chimeric rat/human tp receptors. J Biol Chem. 1997 ; 272 (19). 12399-12405 (Pubitemid 27203327)
36. D'Angelo DD, Eubank JJ, Davis MG, Dorn GW. Mutagenic analysis of platelet thromboxane receptor cysteines. Roles in ligand binding and receptor-effector coupling. J Biol Chem. 1996 ; 271 (11). 6233-6240 (Pubitemid 26098623)
37. Chiang N, Kan WM, Tai HH. Site-directed mutagenesis of cysteinyl and serine residues of human thromboxane a2 receptor in insect cells. Arch Biochem Biophys. 1996 ; 334 (1). 9-17 (Pubitemid 26329795)
38. Komiotis D, Wencel-Drake JD, Dieter JP, Lim CT, Le Breton GC. Labeling of human platelet plasma membrane thromboxane a2/prostaglandin h2 receptors using sqb, a novel biotinylated receptor probe. Biochem Pharmacol. 1996 ; 52 (5). 763-770 (Pubitemid 26276492)
39. Turek JW, Halmos T, Sullivan NL, Antonakis K, Le Breton GC. Mapping of a ligand-binding site for the human thromboxane a2 receptor protein. J Biol Chem. 2002 ; 277 (19). 16791-16797 (Pubitemid 34967701)
40. Khasawneh FT, Huang JS, Turek JW, Le Breton GC. Differential mapping of the amino acids mediating agonist and antagonist coordination with the human thromboxane a2 receptor protein. J Biol Chem. 2006 ; 281 (37). 26951-26965 (Pubitemid 44401724)
41. Chung HO, Yang Q, Catt KJ, Arora KK. Expression and function of the gonadotropin-releasing hormone receptor are dependent on a conserved apolar amino acid in the third intracellular loop. J Biol Chem. 1999 ; 274 (50). 35756-35762 (Pubitemid 129512878)
42. O'Dowd BF, Hnatowich M, Regan JW, Leader WM, Caron MG, Lefkowitz RJ. Site-directed mutagenesis of the cytoplasmic domains of the human beta 2-adrenergic receptor. Localization of regions involved in g protein-receptor coupling. J Biol Chem. 1988 ; 263 (31). 15985-15992 (Pubitemid 18262009)
43. Capra V, Veltri A, Foglia C, Crimaldi L, Habib A, Parenti M, Rovati GE. Mutational analysis of the highly conserved ery motif of the thromboxane a2 receptor: alternative role in g protein-coupled receptor signaling. Mol Pharmacol. 2004 ; 66 (4). 880-889 (Pubitemid 39319460)
44. Moers A, Wettschureck N, Offermanns S. G13-mediated signaling as a potential target for antiplatelet drugs. Drug News Perspect. 2004 ; 17 (8). 493-498 (Pubitemid 39642724)
45. Offermanns S, Simon MI. G alpha 15 and g alpha 16 couple a wide variety of receptors to phospholipase c. J Biol Chem. 1995 ; 270 (25). 15175-15180
46. Kinsella BT, O'Mahony DJ, Fitzgerald GA. The human thromboxane a2 receptor alpha isoform (tp alpha) functionally couples to the g proteins gq and g11 in vivo and is activated by the isoprostane 8-epi prostaglandin f2 alpha. J Pharmacol Exp Ther. 1997 ; 281 (2). 957-964 (Pubitemid 27203832)
47. Berridge MJ, Irvine RF. Inositol trisphosphate, a novel second messenger in cellular signal transduction. Nature. 1984 ; 312 (5992). 315-321 (Pubitemid 15209307)
48. Nishizuka Y. The role of protein kinase c in cell surface signal transduction and tumour promotion. Nature. 1984 ; 308 (5961). 693-698 (Pubitemid 14127666)
49. Faure M, Voyno-Yasenetskaya TA, Bourne HR. Camp and beta gamma subunits of heterotrimeric g proteins stimulate the mitogen-activated protein kinase pathway in cos-7 cells. J Biol Chem. 1994 ; 269 (11). 7851-7854
50. Lamarche N, Hall A. Gaps for rho-related gtpases. Trends Genet. 1994 ; 10 (12). 436-440 (Pubitemid 24352650)
51. Harenberg A, Girkontaite I, Giehl K, Fischer KD. The lsc rhogef mediates signaling from thromboxane a2 to actin polymerization and apoptosis in thymocytes. Eur J Immunol. 2005 ; 35 (6). 1977-1986 (Pubitemid 40862346)
52. Fuse I, Higuchi W, Aizawa Y. Arg60 leu mutation in the first cytoplasmic loop of the platelet thromboxane a2 receptor is not essential for mediating inhibitory coupling between the receptor and adenylyl cyclase. Acta Haematol. 2000 ; 104 (2-3). 95-98 (Pubitemid 32045971)
53. Vezza R, Habib A, FitzGerald GA. Differential signaling by the thromboxane receptor isoforms via the novel gtp-binding protein, gh. J Biol Chem. 1999 ; 274 (18). 12774-12779
54. Feng JF, Rhee SG, Im MJ. Evidence that phospholipase delta1 is the effector in the gh (transglutaminase ii)-mediated signaling. J Biol Chem. 1996 ; 271 (28). 16451-16454 (Pubitemid 26238993)
55. Gutkind JS. Regulation of mitogen-activated protein kinase signaling networks by g protein-coupled receptors. Sci STKE. 2000 ; 2000 ( 40 ):
56. Maier U, Babich A, Macrez N, Leopoldt D, Gierschik P, Illenberger D, et al. Gbeta 5gamma 2 is a highly selective activator of phospholipid-dependent enzymes. J Biol Chem. 2000 ; 275 (18). 13746-13754 (Pubitemid 30257446)
57. Chou KC. Coupling interaction between thromboxane a2 receptor and alpha-13 subunit of guanine nucleotide-binding protein. J Proteome Res. 2005 ; 4 (5). 1681-1686
58. Yan W, Ding Y, Tai HH. 14-3-3zeta interacts with human thromboxane receptors and is involved in the agonist-induced activation of the extracellular-signal-regulated kinase. Biochem Pharmacol. 2006 ; 71 (5). 624-633 (Pubitemid 43121996)
59. Kang H, Lee WK, Choi YH, Vukoti KM, Bang WG, Yu YG. Molecular analysis of the interaction between the intracellular loops of the human serotonin receptor type 6 (5-ht6) and the alpha subunit of gs protein. Biochem Biophys Res Commun. 2005 ; 329 (2). 684-692 (Pubitemid 40311798)
60. Terrillon S, Bouvier M. Roles of g-protein-coupled receptor dimerization. EMBO Rep. 2004 ; 5 (1). 30-34 (Pubitemid 38228524)
61. Laroche G, Lepine MC, Theriault C, Giguere P, Giguere V, Gallant MA, et al. Oligomerization of the alpha and beta isoforms of the thromboxane a2 receptor: Relevance to receptor signaling and endocytosis. Cell Signal. 2005 ; 17 (11). 1373-1383 (Pubitemid 41206647)
62. Sasaki M, Sukegawa J, Miyosawa K, Yanagisawa T, Ohkubo S, Nakahata N. Low expression of cell-surface thromboxane a2 receptor beta-isoform through the negative regulation of its membrane traffic by proteasomes. Prostaglandins Other Lipid Mediat. 2007 ; 83 (4). 237-249 (Pubitemid 46710461)
63. Wilson SJ, McGinley K, Huang AJ, Smyth EM. Heterodimerization of the alpha and beta isoforms of the human thromboxane receptor enhances isoprostane signaling. Biochem Biophys Res Commun. 2007 ; 352 (2). 397-403 (Pubitemid 44838501)
64. Wilson SJ, Roche AM, Kostetskaia E, Smyth EM. Dimerization of the human receptors for prostacyclin and thromboxane facilitates thromboxane receptor-mediated camp generation. J Biol Chem. 2004 ; 279 (51). 53036-53047 (Pubitemid 40051803)
65. Zhang L, DiLizio C, Kim D, Smyth EM, Manning DR. The g12 family of g proteins as a reporter of thromboxane a2 receptor activity. Mol Pharmacol. 2006 ; 69 (4). 1433-1440
66. Feletou M, Vanhoutte PM, Verbeuren TJ. The thromboxane/endoperoxide receptor (tp): the common villain. J Cardiovasc Pharmacol. 2010 ; 55 (4). 317-332
67. Smyth EM. Thromboxane and the thromboxane receptor in cardiovascular disease. Clin Lipidol. 2010 ; 5 (2). 209-219
68. Chandrasekharan NV, Dai H, Roos KL, Evanson NK, Tomsik J, Elton TS, Simmons DL. Cox-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci U S A. 2002 ; 99 (21). 13926-13931 (Pubitemid 35215482)
69. Roth GJ, Stanford N, Majerus PW. Acetylation of prostaglandin synthase by aspirin. Proc Natl Acad Sci U S A. 1975 ; 72 (8). 3073-3076
70. DeWitt DL, el-Harith EA, Kraemer SA, Andrews MJ, Yao EF, Armstrong RL, Smith WL. The aspirin and heme-binding sites of ovine and murine prostaglandin endoperoxide synthases. J Biol Chem. 1990 ; 265 (9). 5192-5198
71. Cipollone F, Patrignani P, Greco A, Panara MR, Padovano R, Cuccurullo F, et al. Differential suppression of thromboxane biosynthesis by indobufen and aspirin in patients with unstable angina. Circulation. 1997 ; 96 (4). 1109-1116 (Pubitemid 27344211)
72. Patrono C. The pgh-synthase system and isozyme-selective inhibition. J Cardiovasc Pharmacol. 2006 ; 47 (suppl 1). S1 - S6
73. Coccheri S. Antiplatelet drugs-do we need new options? With a reappraisal of direct thromboxane inhibitors. Drugs.. 2010 ; 70 (7). 887-908
74. Dogne JM, Hanson J, Pratico D.. Thromboxane, prostacyclin and isoprostanes: therapeutic targets in atherogenesis. Trends Pharmacol Sci. 2005 ; 26 (12). 639-644 (Pubitemid 41636309)
75. Vermylen J, Defreyn G, Carreras LO, Machin SJ, Van Schaeren J, Verstraete M. Thromboxane synthetase inhibition as antithrombotic strategy. Lancet. 1981 ; 1 (8229). 1073-1075 (Pubitemid 11104361)
76. Shapovalova EM, Rudzevich AJ. Effect of inhibitors of arachidonic acid conversion in platelets on thrombin-fibrinogen interaction and thrombin tolerance. Bull Exp Biol Med. 2007 ; 144 (4). 527-528 (Pubitemid 351279771)
77. Coker SJ. Further evidence that thromboxane exacerbates arrhythmias: effects of uk38485 during coronary artery occlusion and reperfusion in anaesthetized greyhounds. J Mol Cell Cardiol. 1984 ; 16 (7). 633-641 (Pubitemid 15044102)
78. Mellow CG, Knight KR, Angel MF, O'Brien BM. Effect of a thromboxane synthetase inhibitor uk-38,485 on the tolerance of skin flaps of primary ischaemia. Aust N Z J Surg. 1990 ; 60 (4). 293-297 (Pubitemid 20273284)
79. Ku EC, McPherson SE, Signor C, Chertock H, Cash WD. Characterization of imidazo[1,5-a]pyridine-5-hexanoic acid (cgs 13080) as a selective thromboxane synthetase inhibitor using in vitro and in vivo biochemical models. Biochem Biophys Res Commun. 1983 ; 112 (3). 899-906 (Pubitemid 13094982)
80. Henriksson P, Rasmanis G, Edhag O, Vesterqvist O, Green K. Thromboxane synthase inhibition: "endoperoxide shunt phenomenon" does not occur in healthy humans in vivo. Prostaglandins. 1990 ; 39 (1). 99-107 (Pubitemid 20042865)
81. Broos K, Feys HB, De Meyer SF, Vanhoorelbeke K, Deckmyn H. Platelets at work in primary hemostasis. Blood Rev. 2011 ; 25 (4). 155-167
82. Uchida Y, Murao S. Effects of thromboxane synthetase inhibitors on cyclical reduction of coronary blood flow in dogs. Jpn Heart J. 1981 ; 22 (6). 971-975 (Pubitemid 12147413)
83. Toki Y, Hieda N, Okumura K, Hashimoto H, Ito T, Ogawa K, et al. Myocardial salvage by a novel thromboxane a2 synthetase inhibitor in a canine coronary occlusion-reperfusion model. Arzneimittelforschung. 1988 ; 38 (2). 224-227 (Pubitemid 18045083)
84. Shibouta Y, Terashita Z, Inada Y, Nishikawa K. Delay of the initiation of hypertension in spontaneously hypertensive rats by cv-4151, a specific thromboxane a2 synthetase inhibitor. Eur J Pharmacol. 1985 ; 109 (2). 135-144 (Pubitemid 15141389)
85. Gorman RR, Johnson RA, Spilman CH, Aiken JW. Inhibition of platelet thromboxane a2 synthase activity by sodium 5-(3′-pyridinylmethyl) benzofuran-2-carboxylate. Prostaglandins. 1983 ; 26 (2). 325-342 (Pubitemid 14206759)
86. Mohrland JS, Vander Lugt JT, Gorman RR, Lakings DB. Thromboxane synthase activity and platelet function after furegrelate administration in man. J Clin Pharmacol. 1989 ; 29 (1). 53-58 (Pubitemid 19058239)
87. Dogne JM, Hanson J, de Leval X, Pratico D, Pace-Asciak CR, Drion P, Pirotte B, Ruan KH. From the design to the clinical application of thromboxane modulators. Curr Pharm Des. 2006 ; 12 (8). 903-923
88. Gresele P, Arnout J, Deckmyn H, Huybrechts E, Pieters G, Vermylen J.. Role of proaggregatory and antiaggregatory prostaglandins in hemostasis. Studies with combined thromboxane synthase inhibition and thromboxane receptor antagonism. J Clin Invest. 1987 ; 80 (5). 1435-1445 (Pubitemid 18027788)
89. Fiddler GI, Lumley P. Preliminary clinical studies with thromboxane synthase inhibitors and thromboxane receptor blockers. A review. Circulation. 1990 ; 81 (suppl 1). 169-178
90. Hanasaki K, Arita H. Characterization of a new compound, s-145, as a specific txa2 receptor antagonist in platelets. Thromb Res. 1988 ; 50 (3). 365-376
91. Ushikubi F, Nakajima M, Hirata M, Okuma M, Fujiwara M, Narumiya S. Purification of the thromboxane a2/prostaglandin h2 receptor from human blood platelets. J Biol Chem. 1989 ; 264 (28). 16496-16501 (Pubitemid 19243538)
92. Bitterman H, Yanagisawa A, Lefer AM. Beneficial actions of thromboxane receptor antagonism in hemorrhagic shock. Circ Shock. 1986 ; 20 (1). 1-11 (Pubitemid 16051828)
93. Tanaka T, Ito S, Higashino R, Fukuta Y, Fukuda Y, Takei M, et al. A new thromboxane receptor antagonist, z-335, ameliorates experimental thrombosis without prolonging the rat tail bleeding time. Thromb Res. 1998 ; 91 (5). 229-235 (Pubitemid 28451943)
94. Ogletree ML, Harris DN, Schumacher WA, Webb ML, Misra RN. Pharmacological profile of bms 180,291: a potent, long-acting, orally active thromboxane a2/prostaglandin endoperoxide receptor antagonist. J Pharmacol Exp Ther. 1993 ; 264 (2). 570-578 (Pubitemid 24283511)
95. Sugimoto H, Shichijo M, Iino T, Manabe Y, Watanabe A, Shimazaki M, et al. An orally bioavailable small molecule antagonist of crth2, ramatroban (bay u3405), inhibits prostaglandin d2-induced eosinophil migration in vitro. J Pharmacol Exp Ther. 2003 ; 305 (1). 347-352 (Pubitemid 36373870)
96. Ashida Y, Matsumoto T, Kuriki H, Shiraishi M, Kato K, Terao S. A novel anti-asthmatic quinone derivative, aa-2414 with a potent antagonistic activity against a variety of spasmogenic prostanoids. Prostaglandins. 1989 ; 38 (1). 91-112 (Pubitemid 19184300)
97. Gresele P, Deckmyn H, Arnout J, Nenci GG, Vermylen J. Characterization of n, n′-bis(3-picolyl)-4-methoxy-isophtalamide (picotamide) as a dual thromboxane synthase inhibitor/thromboxane a2 receptor antagonist in human platelets. Thromb Haemost. 1989 ; 61 (3). 479-484 (Pubitemid 19168159)
98. Gresele P, Deckmyn H, Arnout J, Lemmens J, Janssens W, Vermylen J. Bm 13.177, a selective blocker of platelet and vessel wall thromboxane receptors, is active in man. Lancet. 1984 ; 1 (8384). 991-994 (Pubitemid 14148895)
99. Janssens WJ, Deckmyn H, Gresele P, Vermylen J. Bm 13.177 selectively inhibits endoperoxide analogue induced vascular contractions. Arch Int Pharmacodyn Ther. 1985 ; 276 (1). 28-34 (Pubitemid 16240023)
100. Gaussem P, Reny JL, Thalamas C, Chatelain N, Kroumova M, Jude B, et al. The specific thromboxane receptor antagonist s18886: Pharmacokinetic and pharmacodynamic studies. J Thromb Haemost. 2005 ; 3 (7). 1437-1445 (Pubitemid 41725201)
101. Simonet S, Descombes JJ, Vallez MO, Dubuffet T, Lavielle G, Verbeuren TJ. S 18886, a new thromboxane (tp)-receptor antagonist is the active isomer of s 18204 in all species, except in the guinea-pig. Adv Exp Med Biol. 1997 ; 433: 173-176 (Pubitemid 28231807)
102. Osende JI, Shimbo D, Fuster V, Dubar M, Badimon JJ. Antithrombotic effects of s 18886, a novel orally active thromboxane a2 receptor antagonist. J Thromb Haemost. 2004 ; 2 (3). 492-498 (Pubitemid 40185663)
103. Cheng Y, Austin SC, Rocca B, Koller BH, Coffman TM, Grosser T, et al. Role of prostacyclin in the cardiovascular response to thromboxane a2. Science. 2002 ; 296 (5567). 539-541 (Pubitemid 34408674)
104. Cayatte AJ, Du Y, Oliver-Krasinski J, Lavielle G, Verbeuren TJ, Cohen RA. The thromboxane receptor antagonist s18886 but not aspirin inhibits atherogenesis in apo e-deficient mice: evidence that eicosanoids other than thromboxane contribute to atherosclerosis. Arterioscler Thromb Vasc Biol. 2000 ; 20 (7). 1724-1728 (Pubitemid 30470586)
105. Belhassen L, Pelle G, Dubois-Rande JL, Adnot S. Improved endothelial function by the thromboxane a2 receptor antagonist s 18886 in patients with coronary artery disease treated with aspirin. J Am Coll Cardiol. 2003 ; 41 (7). 1198-1204 (Pubitemid 36384909)
106. Lumley P, White BP, Humphrey PP. Gr32191, a highly potent and specific thromboxane a2 receptor blocking drug on platelets and vascular and airways smooth muscle in vitro. Br J Pharmacol. 1989 ; 97 (3). 783-794 (Pubitemid 19168712)
107. Gottstein N, Ewins BA, Eccleston C, Hubbard GP, Kavanagh IC, Minihane AM, et al. Effect of genistein and daidzein on platelet aggregation and monocyte and endothelial function. Br J Nutr. 2003 ; 89 (5). 607-616
108. Navarro-Nunez L, Lozano ML, Palomo M, Martinez C, Vicente V, Castillo J, et al. Apigenin inhibits platelet adhesion and thrombus formation and synergizes with aspirin in the suppression of the arachidonic acid pathway. J Agric Food Chem. 2008 ; 56 (9). 2970-2976 (Pubitemid 351746016)
109. Iwashita M, Oka N, Ohkubo S, Saito M, Nakahata N. Piperlongumine, a constituent of piper longum l., inhibits rabbit platelet aggregation as a thromboxane a(2) receptor antagonist. Eur J Pharmacol. 2007 ; 570 (1-3). 38-42 (Pubitemid 47247693)
110. Greenberg SS, Johns A, Kleha J, Xie J, Wang Y, Bianchi J, et al. Phenol red is a thromboxane a2/prostaglandin h2 receptor antagonist in canine lingual arteries and human platelets. J Pharmacol Exp Ther. 1994 ; 268 (3). 1352-1361 (Pubitemid 24100353)
111. Randomized trial of ridogrel, a combined thromboxane a2 synthase inhibitor and thromboxane a2/prostaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myocardial infarction. The ridogrel versus aspirin patency trial (rapt). Circulation. 1994 ; 89 (2). 588-595
112. Soyka R, Guth BD, Weisenberger HM, Luger P, Muller TH. Guanidine derivatives as combined thromboxane a2 receptor antagonists and synthase inhibitors. J Med Chem. 1999 ; 42 (7). 1235-1249 (Pubitemid 29181146)
113. Selg E, Buccellati C, Andersson M, Rovati GE, Ezinga M, Sala A, et al. Antagonism of thromboxane receptors by diclofenac and lumiracoxib. Br J Pharmacol. 2007 ; 152 (8). 1185-1195 (Pubitemid 350242444)
114. Dogne JM, Rolin S, de Leval X, Benoit P, Neven P, Delarge J, et al. Pharmacology of the thromboxane receptor antagonist and thromboxane synthase inhibitor bm-531. Cardiovasc Drug Rev. 2001 ; 19 (2). 87-96 (Pubitemid 32703319)
115. Rolin S, Hanson J, Vastersaegher C, Cherdon C, Pratico D, Masereel B, et al. Bm-520, an original txa2 modulator, inhibits the action of thromboxane a2 and 8-iso-prostaglandin f2alphain vitro and in vivo on human and rodent platelets, and aortic vascular smooth muscles from rodents. Prostaglandins Other Lipid Mediat. 2007 ; 84 (1-2). 14-23 (Pubitemid 47069930)
116. Dogne JM, de Leval X, Kolh P, Sanna V, Rolin S, Michaux C, et al. Pharmacological evaluation of the novel thromboxane modulator bm-567 (i/ii). Effects of bm-567 on platelet function. Prostaglandins Leukot Essent Fatty Acids.. 2003 ; 68 (1). 49-54 (Pubitemid 36197486)
117. Rolin S, Dogne JM, Michaux C, Delarge J, Masereel B. Activity of a novel dual thromboxane a(2)receptor antagonist and thromboxane synthase inhibitor (bm-573) on platelet function and isolated smooth muscles. Prostaglandins Leukot Essent Fatty Acids. 2001 ; 65 (2). 67-72 (Pubitemid 32928138)
118. Yamada N, Miyamoto M, Isogaya M, Suzuki M, Ikezawa S, Ohno M, et al. Tra-418, a novel compound having both thromboxane a(2) receptor antagonistic and prostaglandin i(2) receptor agonistic activities: Its antiplatelet effects in human and animal platelets. J Thromb Haemost. 2003 ; 1 (8). 1813-1819
119. Arakida Y, Suwa K, Ohga K, Yokota M, Miyata K, Yamada T, et al. In vitro pharmacologic profile of ym158, a new dual antagonist for ltd4 and txa2 receptors. J Pharmacol Exp Ther. 1998 ; 287 (2). 633-639 (Pubitemid 29133663)
120. Arakida Y, Ohga K, Suwa K, Yokota M, Miyata K, Yamada T, et al. Effects of lipid mediator antagonists on predominant mediator-controlled asthmatic reactions in passively sensitized guinea pigs. J Pharmacol Exp Ther. 1999 ; 290 (3). 1285-1291 (Pubitemid 29400271)
121. Kalinowski L, Matys T, Chabielska E, Buczko W, Malinski T. Angiotensin ii at1 receptor antagonists inhibit platelet adhesion and aggregation by nitric oxide release. Hypertension. 2002 ; 40 (4). 521-527
122. Schwemmer M, Sommer O, Bassenge E. Angiotensin receptor blocker losartan suppresses platelet activity by interfering with thromboxane signaling. Cardiovasc Drugs Ther. 2001 ; 15 (4). 301-307 (Pubitemid 33121983)
123. Hakim A, Stanke-Labesque F, Hoffmann P, Sessa C, Caron F, Cracowski JL, et al. Functional comparison of the antagonistic properties of some angiotensin ii type 1 receptor blockers on the contraction elicited by angiotensin ii and thromboxane a2 on human saphenous veins. J Cardiovasc Pharmacol. 2003 ; 42 (1). 42-47 (Pubitemid 36798040)
124. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation. 1998 ; 98 (19). 2088-2093 (Pubitemid 28512236)
125. Lee JJ, Jin YR, Yu JY, Munkhtsetseg T, Park ES, Lim Y, et al. Antithrombotic and antiplatelet activities of fenofibrate, a lipid-lowering drug. Atherosclerosis. 2009 ; 206 (2). 375-382
126. Ishimura M, Maeda T, Kataoka S, Suda M, Kurokawa S, Hiyama Y. Effects of kp-496, a novel dual antagonist for cysteinyl leukotriene receptor 1 and thromboxane a2 receptor, on sephadex-induced airway inflammation in rats. Biol Pharm Bull. 2009 ; 32 (6). 1057-1061
127. Ueda K, Komine J, Matsuo M, Seino S, Amachi T. Cooperative binding of atp and mgadp in the sulfonylurea receptor is modulated by glibenclamide. Proc Natl Acad Sci U S A. 1999 ; 96 (4). 1268-1272 (Pubitemid 29098440)
128. Kemp BK, McPherson GA. Interspecies differences in thromboxane a2 receptors are distinguished by glibenclamide. Eur J Pharmacol. 1998 ; 354 (2-3). 173-178 (Pubitemid 28401450)
129. Ting HJ, Murray WJ, Khasawneh FT. Repurposing an old drug for a new use: glybenclamide exerts antiplatelet activity by interacting with the thromboxane a(2) receptor. Acta Pharmacol Sin. 2010 ; 31 (2). 150-159
130. Ting HJ, Khasawneh FT. Glybenclamide: an antidiabetic with in vivo antithrombotic activity. Eur J Pharmacol. 2010 ; 649 (1-3). 249-254